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expression is associated with increased risk of
recurrence and death in triple-negative breast
cancer patients
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Background: Small breast epithelial mucin (SBEM) has been implicated in tumor genesis and micrometastasis in
breast cancer. Triple-negative breast cancer (TNBC) was characterized by high incidence in young women,early
relapse and a very poor prognosis. The aim of this study was to evaluate the association of SBEM expression in
tissues of TNBC with disease-free survival (DFS) and overall survival (OS).
Methods: SBEM protein expression was detected in 87 available formalin-fixed paraffin-embedded (FFPE) tissue
specimens from TNBC patients by means of immunohistochemistry (IHC). We analyzed the correlation between
the SBEM protein expression and DFS and OS during a 5 year follow-up period, respectively. And a SBEM cut-off
value of prognosis was established associated with DFS and OS. SBEM was analyzed against other risk factors in
multivariate analysis.
Results: SBEM 3+ score was cut-off value of prognosis and significantly correlated with DFS (p = 0.000) and OS
(p = 0.001) in TNBC patients. There was a marked associations (p <0.05) between SBEM 3+ score and tumor size,
grade, node status, TNM stage and Ki67. Multivariate analysis showed that patients with SBEM 3+ represented a
higher risk of recurrence and mortality than those with a lower SBEM expression (HR = 3.370 with p = 0.008 for
DFS and HR = 4.185 with p = 0.004 for OS).
Conclusions: SBEM is an independent risk predictor and may offer utility as a prognostic marker in TNBC patients.
Virtual Slides: http://www.diagnosticpathology.diagnomx.eu/vs/1624613061936917
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Breast cancer remains to be an important public health
problem. Triple-negative breast cancer (TNBC), one of five
molecular subtypes recognized in 2000 [1,2], lacks estrogen
receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) expression.
TNBC is characterized by high incidence in young
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reproduction in any medium, provided the orchemotherapy. Most studies [3-5] showed that the progno-
sis of TNBC was less favorable than that of non- TNBC.
Therefore, more attention is being paid to unraveling the
oncogenes that expressing at inappropriately high levels or
being altered to have novel properties, which leads to inva-
sion and metastasis of carcinoma cells [6]. Small breast epi-
thelial mucin (SBEM) is a newly cloned gene and expresses
in breast cancer cell lines rather than in cell lines of non-
breast origin [7]. SBEM was only expressed in mammary
and salivary glands [7]. High SBEM expression was found
to be strongly associated with the histopathological detec-
tion of lymph node metastases [7]. Several laboratories
showed that SBEM expression correlated with higher
tumor grade [8], TNM staging and lymph node metastasisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more frequently observed in ER- than in ER + breast can-
cers [8,10] and SBEM expression showed a trend towards
an association with decreased OS and DFS in SBEM+ pa-
tients [8]. Valladares Ayerbes et al. [10] studied the expres-
sion profiles of SBEM gene in silico and in vitro, and
demonstrated that SBEM-mRNA could serve as a marker
for bone marrow micro metastasis in breast cancer patients
[10]. Researchers also reported that SBEM had the poten-
tial to be a specific marker for predicting hematogenous
micro metastasis and responses to neo-adjuvant chemo-
therapy in breast cancer [9].
Based on the above information, SBEM might play an
important role in progression and metastasis of breast
cancer, especially in TNBC. The aim of this study was to
analyze association of SBEM expression in tissue of TNBC
with clinical- pathological features, DFS and OS, and to
identify new prognostic and/or predictive biomarkers for
TNBC patients.
Materials and methods
The study examined cases from 126 patients diagnosed
between 2006 and 2008 in our hospital. 39 cases without
evaluable tumor tissue were excluded from the analysis.Table 1 Clinicopathological characteristics of patients





X > 35 55
X≤ 35 21















X > 20 mm 40
X≤ 20 mm 36
Ki67 71 62
X > 35 19
X≤ 35 39The final database for analysis included 87 cases with
histological confirmation. Clinical data of all the cases
were reviewed retrospectively from medical records in our
hospital. All patients were females and had a minimum 5
years’ follow-up records. All the patients underwent oper-
ational treatment according to clinical practice guidelines
of National Comprehensive Cancer Network (NCCN) of
the United States. None of the patients received neo-
adjuvant therapy. Statistic and analysis of clinicopathologi-
cal parameters, including age at diagnosis, disease stage,
tumor size, tumor grade, lymph node status and Ki67,
were listed in Table 1.
All cases examined were ER and PR negative by IHC.
HER2 status was considered negative if the immunohis-
tochemical score was 0 or 1+, or if the score was 2+ but
non-amplification by fluorescence in situ hybridization
(FISH), and positive if the score was 3 +.
SBEM expression and evaluation of IHC
All tissues were collected surgically under the supervision
of an experienced pathologist. SBEM expression was mea-
sured by IHC on FFPE samples.
Streptavidinperosidase (S-P) IHC staining was performed
using SBEM antibody of mouse monoclonal (diluted 1/3 score SBEM= 3 score P-value
(n) % Number (n) %
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were done as described by Jennbacken [11].
PBS was used to replace the primary antibody in nega-
tive controls. SBEM was a secreted protein and it was
mainly located in cell membrane, subordinately in cyto-
plasm. Normal breast tissues were in general weakly or
negative. So it was evaluated and scored if cell mem-
brane and/or cytoplasm reactivity were observed [8]. But
there was no relevant clinical cut-off point and the
standard evaluation methods reported for SBEM in the
literature. According to our data and TMA IHC grading
method by Serrero G [12] and Pan [13], our scoring was
semiquantitatively categorized as: ≤5% of tumor cells
staining with/without weakly stained was negative (0),
followed by a score of 1 (>5% of tumor cells and with
weak/focal positive staining or ≤5% of tumor cells with
strongly stained), 2 (>5% of tumor cells and with moder-
ate/focal positive staining), 3 (>5% of tumor cells and
with strong/diffuse positive staining).
Statistical analysis
The correlation between SBEM, Clinicopathological char-
acteristics and survival outcomes was compared by
Pearson’s Χ2 test. Survival analyses, including DFS and OS,
were performed with the log rank test and all results were
displayed in Kaplan–Meier. DFS was defined as the time
interval from date of diagnosis to the time of last disease-
free follow-up or at death for those patients who diedFigure 1 Immunohistochemical staining for SBEM. A: 0+: ≤5% of tumo
magnification × 200); B: 1+: >5% of tumor cells and with weak/focal positiv
magnification × 100); C: 2+: >5% of tumor cells and with moderate/focal p
and with strong/diffuse positive staining (original magnification × 200).without a previous recurrence. OS was defined as the time
interval from date of diagnosis to time of last follow-up or
death [14]. Time to recurrence (local, regional and distant)
was censored at time of last disease-free follow-up, and at
death for those patients who died without a previous recur-
rence [14]. Statistical significance was defined as P value <
0.05. SPSS17.0 software package was used for all statistical
analyses.
In order to observe whether the SBEM expression had an
independent prognostic value with conventional risk fac-
tors, the risk factor alone, or along with SBEM was analyzed
with Cox’s proportional hazards models. Multivariate ana-
lysis was performed to determine the association of SBEM
with all combined clinical risk factors on DFS and OS.
Results
The clinicopathological characteristics of patients were
described in Table 1. In the whole group, the median age
was 42 (from 24 to 67) years old, the median DFS was 23
months (from 2 to 54 months) and median OS was 34
months (from 6 to 60 months). Figure 1 showed photo-
micrograph examples of SBEM expression with different
scores in TNBC tissues determined by IHC.
To evaluate SBEM prognostic significance, we analyzed
SBEM score (0, 1+, 2+, and 3+) in relation with DFS and
OS in TNBC patients. No significant difference was found
between DFS or OS and each group (SBEM score of 0, 1+
and 2+) by pairwise comparison methods (p >0.05). But,r cells staining with/without weakly stained was negative (original
e staining or ≤5% of tumor cells with strongly stained (original
ositive staining (original magnification × 200); D: 3+: >5% of tumor cells
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and SBEM score of 0, 1+ and 2+ (p <0.05) (Figure 2). The
results of log-rank testing for SBEM different scores were
showed in Table 2.
We observed that high SBEM expression with SBEM 3+
score was consistent with high recurrence and death rates,
while lower SBEM expression (0, 1+ and 2+) was reversed.
Based on the statistics above, we believed that SBEM ex-
pression with SBEM 3+ score might be the SBEM cut-off
value of prognosis. We divided the cases into two groups,
one is the SBEM< 3+ group, the other is SBEM= 3+
group. From Figure 3, we found that DFS and OS functionFigure 2 Kaplan-Meier estimates for DFS and OS by SBEM scores. No
and 2+) and DFS (A) or OS (B) (p >0.05). But, there was a marked differenc
on DFS (A) and OS (B).curves showed the large separation between SBEM< 3+
group and SBEM= 3+ group. The log-rank tests con-
firmed that SBEM score of 3+ was significant associated
with DFS and OS (p = 0.000, p = 0.001, respectively). The
results of log-rank testing for SBEM score cut-off were
showed in Table 3. According to these results, the thresh-
old effect of SBEM score 3+ was verified.
On the basis of the cut-off established, 87 patients
were divided into 2 groups. Table 1 showed that there
were significant associations between SBEM 3+ score
and nodal involvement, TNM stage and Ki67 (p < 0.05).
Neither SBEM< 3+ group nor SBEM= 3+ group, SBEMA
B
significant difference was found between different SBEM score (0, 1+
e between SBEM 3+ score and SBEM score of 0, 1+ and 2+ (p <0.05)
Figure 3 Kaplan-Meier estimates for DFS and OS by SBEM < 3+ group
SBEM =3 + group and SBEM score <3+ group on DFS (A) and OS (B) (p = 0




Chi-squared P Value Chi-squared P Value
0 and 1 0.020 0.887 0.124 0.724
0 and 2 0.147 0.701 0.160 0.689
0 and 3 22.641 0.000 15.472 0.000
1 and 2 0.087 0.768 0.623 0.430
1 and 3 12.501 0.000 9.431 0.002
2 and 3 6.578 0.010 5.512 0.019
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http://www.diagnosticpathology.org/content/8/1/71expression indicated no significant correlations with age,
tumor size and grade. Based on the Kaplan Meier curves
for DFS and OS function, the median DFS and OS of
SBEM< 3+ group were 28 and 39 months, respectively,
while those of SBEM= 3+ group were only 12 and 25
months, respectively. Patients with high SBEM expression
had poor clinical outcomes. In SBEM= 3+ group, no pa-
tients could survive over 5 years. The longest time of OS
was 38 months. In comparison, the patients in SBEM< 3+
group had the higher survival probabilities and longer OSA
B
and SBEM = 3+ group. There was a significant difference between
.000, p = 0.001, respectively).





Chi-squared P Value Chi-squared P Value
0 and 1 0.020 0.887 0.124 0.724
0,1 and 2 0.120 0.729 0.399 0.528
0,1,2 and 3 23.524 0.000 11.595 0.001
A
B
Figure 4 Kaplan-Meier estimates for DFS and OS in lymph node posit
with DFS and OS in both lymph node positive (A, B) and negative group (
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in SBEM< 3+ group had a higher risk of recurrence or
death than those in SBEM< 3+ group.
Similar observations of Kaplan Meier curves for DFS and
OS function were obtained when the cases were segregated
into lymph node negative and positive group (Figure 4).
The results of log-rank testing for lymph node positive
group and negative group were showed in Table 4.
Univariate analysis showed that SBEM 3+ scores were
associated with an HR of 5.768 for DFS and 4.113 for
OS in Table 5 and Table 6. It was demonstrated thatC
D
ive and negative group. SBEM score of 3+ was significant associated
C, D) (p <0.05).
Table 4 Log-rank testing for lymph node positive group
and lymph node negative group
Lymph node DFS OS
Chi-squared P Value Chi-squared P Value
positive 9.392 0.002 4.525 0.033
negative 9.960 0.002 5.524 0.019
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DFS and OS were other predictors of survival. From
Table 5, we found that there was no marginally change
when SBEM was added to each covariate in DFS. Similar
results were showed for OS in Table 6.
Finally, SBEM and other clinical risk factors, including
grade, disease stage, lymph node status and Ki67, were
combined to determine the associations by multivariate
analysis. Table 7 showed that HR for SBEM adjusted for
the other risk factors remained unaffected and signifi-
cant (HR = 3.370 with p = 0.008 for DFS and HR = 4.185
with p = 0.004 for OS).Discussion
Breast cancer is pushed into first place in the United
States and many other parts of world. Breast cancer alone
is expected to account for 29% (226,870) of all new cancer
cases among women [15]. Although incidence rate of
breast cancer remains relatively stable in recent 5 years, its
death rate declines by 34% because of the development of
diagnosis and targeting medication. TNBC accounts for
about 15% of all breast cancers. Patients with TNBC are
more likely to experience death and distant recurrence
compared to those with other cancers, and the median
time to death/distant recurrence is significantly shortened.
TNBC is one of solid tumors which are sensitive to
chemotherapy, but other modalities, such as endocrine
and targeted therapy, are not applicable. So, it is crucial to




SBEM (3+ vs. <3+) 0.000 0.000
Lymph Node (Pos. vs. Neg.) 0.000 0.000
Age (>35Y vs. ≤35Y) 0.749 0.785
Tumor size (>20 mm vs. ≤20 mm) 0.457 0.583
Grade (>1 vs. =1) 0.035 0.053
Grade (=3 vs. ≤2) 0.000 0.001
TNM (>1 vs. =1) 0.000 0.000
TNM (=3 vs. ≤2) 0.000 0.000
Ki67 (≤35 vs. >35) 0.001 0.004provide useful information to guide early therapeutic
methods of TNBC patients.
Although various biological markers had been proposed
for the detection of breast cancer cells, they were often af-
fected by tumor differentiation, lower specificity and detec-
tion rate. Cyclin D1 was an effective marker for the
differential diagnosis of other papillary lesions. Because
Cyclin D1expressed in both lesions, it could not be used to
distinguish between papilloma and papillary carcinoma le-
sions [16]. Petra Barros et al. found that the expression of
β1 integrin had an impact in disease-specific survival
(number of months from diagnosis to the time of death
due to breast cancer) and could be a marker of poor prog-
nosis in breast cancer [17]. But, β1 integrin played a role in
predicting the clinical course and prognosis of several types
of cancers [18], especially abundant expressing in Non-
small-cell lung carcinoma [19]. By the same token,
carcinoembryonic antigen (CEA) was not a specific marker
of breast cancer because it was expressed at high levels in
a variety of human tissues including lung, breast, and colo-
rectal cancer. Although BRCA1 was associated with the
genesis, progression, and prognosis of young breast cancer
patients [20], they only accounted for about 5% of breast
cancer occurrences [21]. So, researchers are searching for
more promising genes to improve the screen, diagnosis
and prognosis predicting of breast cancer.
SBEM was tissue-specific protein and only expresses in
mammary and salivary glands [7]. SBEM could serve as a
useful marker for breast nodal metastasis, and for detection
of micro metastatic cells within lymph nodes. Also, it was
used for the differential diagnosis of the primary origin of
an unknown metastasis, especially in high grade and ER/
PR-negative tumors [7]. Hinde et al. confirmed that the pre-
dictive power of IHC criteria appeared to be similar to that
of gene expression analysis. The IHC information could be
used to improve therapeutic decisions, mainly for luminal
B, Her2- over-expressing and basal-like subtypes [22]. So,
we examined SBEM levels in FFPE tissue sections by IHC
test and then analyzed the correlation of SBEM expressionCox’s proportional hazards analysis
Hazard radio 95% Confidence interval
Univariate Added SBEM Univariate Added SBEM
5.768 5.768 2.584-12.876 2.584-12.876
3.589 3.433 1.996-6.451 1.893-6.228
1.103 0.918 0.606-2.006 0.495-1.702
0.814 0.858 0.473-1.400 0.498-1.480
2.052 1.911 1.053-3.999 0.991-3.799
3.930 3.549 1.905-8.110 1.699-7.413
3.439 3.148 1.925-6.143 1.816-5.459
5.647 5.446 2.601-12.264 2.401-12.352
3.060 2.714 1.576-5.942 1.366-5.393
Table 6 The impact of SBEM and other risk factors on OS by Cox’s proportional hazards analysis
Covariate
P value Hazard radio 95% Confidence interval
Univariate Added SBEM Univariate Added SBEM Univariate Added SBEM
SBEM (3+ vs. <3+) 0.000 0.000 4.113 4.113 2.004-8.440 2.004-8.440
Lymph Node (Pos. vs. Neg.) 0.000 0.000 2.972 2.734 1.777-4.970 1.617-4.623
Age (>35Y vs. ≤35Y) 0.646 0.942 1.140 0.979 0.652-1.992 0.551-1.738
Tumor size (>20 mm vs. ≤20 mm) 0.308 0.367 0.771 0.794 0.468-1.271 0.481-1.311
Grade (>1 vs. =1) 0.066 0.085 0.563 1.720 0.305-1.040 0.928-3.188
Grade (=3 vs. ≤2) 0.001 0.004 3.036 2.688 1.572-5.864 1.371-5.273
TNM (>1 vs. =1) 0.000 0.000 3.164 2.769 1.918-5.218 1.705-4.498
TNM (=3 vs. ≤2) 0.000 0.001 4.000 3.565 1.987-8.055 1.734-7.332
Ki67 (≤35 vs. > 35) 0.001 0.004 2.956 2.597 1.585-5.512 1.362-4.950
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http://www.diagnosticpathology.org/content/8/1/71with DFS and OS. Liu et al. reported that SBEM protein ex-
pression correlated with tumor size, TNM staging and
lymph node metastasis [9]. Ki67 is used to assess the prog-
nosis of cancer patients [23]. It would be indicated that
SBEM were related to prognostic value with Ki67. Overall
these risk factors, including age, grade, size, disease stage,
lymph node status, and Ki67, were analyzed in our study.
Our data showed that the detection rate of SBEM in FFPE
tissue of TNBC was 58%, which was higher than previous
report [8]. SBEM expression levels positively correlated
with DFS and OS in TNBC patients. The Cox’s propor-
tional hazards regression model showed that SBEM was in-
dependent for grade, age, disease stage, lymph node status,
and Ki67. When we adjusted SBEM to combine with each
clinical risk factor, SBEM expression still remained signifi-
cant. Multivariate analysis showed that patients with a high
SBEM expression of 3+ represented a higher risk of recur-
rence and mortality than those with a low SBEM expres-
sion (HR = 3.370 with p = 0.008 for DFS and HR= 4.185
with p = 0.004 for OS). SBEM could be regarded as an inde-
pendent prognostic factor in TNBC.
We believed that SBEM would show much more ad-
vantages than other protein–based biomarkers and would
be used as prognostic indicator. Meanwhile, SBEM ex-
pression in PB (Peripheral blood) of breast cancer patientsTable 7 Multivariate analysis results of SBEM with other risk
Covariate DFS
P value Hazard radio 95% Confiden
SBEM (3+ vs. <3+) 0.008 3.370 1.382-8.218
Lymph Node (Pos. vs. Neg.) 0.751 1.195 0.398-3.585
Grade (=3 vs ≤2) 0.934 1.054 0.306-3.630
TNM (>1 vs. =1) 0.489 1.441 0.513-4.050
TNM (=3 vs. ≤2) 0.001 3.851 1.744-8.500
Ki67 (≤35 vs. >35) 0.152 2.022 0.771-5.301was markedly higher than that of healthy donors and
other cancer patients [9]. Determination of SBEM protein
in tissue and mRNA expression in PB of TNBC patients
maybe helpful for early diagnosis, choice of treatment, de-
cision of the degree of malignancy and risk prediction of
recurrence. However, it is necessary to determine the
function of a certain gene by carrying out large sample
studies or a large meta-analysis in different institutions
and hospitals. In the past decade, the findings about
the relationship between Catechol-O-methyltransferase
Val158Met (COMT Val108/158Met) polymorphism and
breast cancer risk were inconsistent. A large meta-analysis
conducted by Xue Qin confirmed that COMT Val108/
158Met polymorphism may not be associated with breast
cancer risk [24]. Similarly, the prognostic significance of
SBEM needs further evidence in TNBC patients.
Due to different breast cancer subtype are associated
with different gene expression patterns, it is significant
to identify the particular gene to suit the proper bio-
logical characteristic of a certain type of primary tumor.
SBEM over-expression maybe the special characteristic
of tumor cells in TNBC. In conclusion, we have done some
really nice research in which SBEM shows its prognostic
value in TNBC. Our findings may eventually lead to wide
application of SBEM as a tumor marker or a target gene forfactors on DFS and OS
OS
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http://www.diagnosticpathology.org/content/8/1/71therapy and rapid development in the diagnostic and thera-
peutic products for TNBC patients in future.
Conclusion
We have demonstrated that SBEM is differentially expressed
in TNBC patients by immunostaining and SBEM may be
best viewed as an independent prognostic factor of DFS and
OS. The expression of SBEM does significantly correlate
with a DFS and an OS of TNBC patients. We suggest that
SBEM could be a promising prognostic biomarker in TNBC
patients for cancer diagnostics, as well as be a possible target
for the treatment of TNBC patients.
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